


HOW LONG FOR A VACCINE TO REACH EUROPEAN POPULATION ?

TIME BETWEEN MARKETING AUTHORISATION & POPULATION ACCESS



WHAT IS A NITAG?

NITAGs ARE FORMALLY ESTABLISHED **N**ATIONAL **I**MMUNISATION **T**ECHNICAL **A**DVISORY **G**ROUPS THAT GUIDE **I**MMUNISATION POLICIES*



They are established in the majority of countries



They provide guidance to national policy-makers to support evidence-based immunisation policies and include vaccines in national immunisation programmes

* National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening, P Duclos, Vaccine. 2010 Apr 19;28 Suppl 1:A18-25. doi: 10.1016/j.vaccine.2010.02.027

POPULATION ACCESS TO NEW VACCINES IN EUROPE

A 2009 SURVEY**

17 EUROPEAN COUNTRIES



Austria



Belgium



Bulgaria



Czech Rep.



Finland



France



Germany



Ireland



Italy



Netherlands



Poland



Portugal



Spain



Sweden



Slovakia



Switzerland



UK


3 VACCINATIONS



PNEUMOCOCCAL conjugate vaccine



ROTAVIRUS vaccine



HUMAN PAPILLOMAVIRUS vaccine



POPULATION ACCESS WAS CONSIDERED ACHIEVED WHEN A STUDY VACCINE RECEIVED :



a positive advice,



was funded,




and available for national immunisation.



6,4 YEARS

median time lag between Marketing Authorisation and effective Population Access



>90%

of the entire access period corresponds to the development of a vaccination advice / recommendation by NITAGs

HOW WERE THESE MARKET ACCESS TIMEFRAMES CALCULATED ?

BETWEEN



MARKETING AUTHORISATION



POPULATION ACCESS

OR BETWEEN



MARKETING AUTHORISATION



DATE OF STUDY COMPLETION

July 31, 2009

HOW MANY

OF THESE 3 VACCINATIONS WERE AVAILABLE, RECOMMENDED AND FUNDED BY THE END OF THE STUDY ?


0/3 VACCINATIONS



1/3 VACCINATIONS



2/3 VACCINATIONS



3/3 VACCINATIONS



Except in Belgium, EU populations did not have access to all 3 new vaccinations by the end of July 2009.

** PR Blank et al. Population access to new vaccines in European countries. Vaccine. 2013 Jun 12;31(27):2862-7. doi: 10.1016/j.vaccine.2013.04.039. Epub 2013 Apr 28 |

HOW TO REDUCE DELAYS ?



EXISTENCE OF AN OFFICIAL LIMITED TIMEFRAME TO TAKE DECISIONS AND/OR MAKE THEM PARTLY/ FULLY PUBLIC



OFFICIAL LINK BETWEEN THE EVALUATING BODY AND THE MINISTRY OF HEALTH